RxDoctor Payments DataLook up a doctor →

Natale Sheehan, MD

Medical Oncology · Jackson, MSNPI 1518178524

Payments from drug & device makers

$82,076in general payments, 2019–2025

Across 240 payments — averaging $341.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mirati Therapeutics, Inc.$68K
  • Eli Lilly$10K
  • Johnson & Johnson$429
  • Bristol Myers Squibb$389
  • Gilead$337
  • Merck$315
  • plus $2K from 43 others

What the payments were for

  • Food & beverage$3,93498%
  • Education$632%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$82,076 in reported general payments places this provider in the 90th percentile of 20 medical oncology providers in Mississippi.

See all medical oncology providers in Mississippi

Medicare billing

Part B allowed, 2024
$5,029,355
Medicare patients
818
Services billed
208,898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide78$1,186,057
BrukinsaZanubrutinib29$397,560
ImbruvicaIbrutinib25$372,371
RevlimidLenalidomide26$366,824
LynparzaOlaparib16$260,361
FruzaqlaFruquintinib11$245,156
VerzenioAbemaciclib12$177,849
TavalisseFostamatinib Disodium12$170,537
ZarxioFilgrastim-Sndz18$38,542
Abiraterone Acetate12$27,000
EliquisApixaban14$15,837
Exemestane16$6,496
Letrozole345$4,442
Tamoxifen Citrate134$3,094
Imatinib Mesylate15$2,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$41$397,56029 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$115$372,37125 claims
Bristol Myers SquibbRevlimid$389$366,82426 claims
AstraZenecaLynparza$207$260,36116 claims
Takeda Pharmaceuticals U.S.A., Inc.Fruzaqla$12$245,15611 claims
PfizerEliquis$226$15,83714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 20 medical oncology providers in Mississippi.

Other medical oncology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →